Introduction: Epidemiological and experimental studies have suggested that chronic H. pylori infection may be associated with colorectal cancer (CRC), a topic of growing interest. The Bradford-Hill criteria are the mainstay of the epidemiological approach to causal inference. We aim to evaluate the epidemiological evidence based on the Bradford-Hill causality criteria and the association between H. pylori and CRC.
Methodology: A literature review of the databases search: Pubmed, ScienceDirect, Embase, SciELO, Cochrane, and Medline. There are no limits in a period. Information sources that were coherent with the objectives set were selected.
Results: Applying the Bradford Hill criteria, we can conclude that H. pylori is positively associated with CRC. The current epidemiological findings should stimulate future studies to explain how H. pylori interacts with intestinal dysbiosis and the role of H. pylori eradication in the treatment and prevention of CRC.
Conclusions: H. pylori reasonably meets the Bradford Hill criteria for causality. Further studies are required to consolidate the data and generate strategies to determine whether H. pylori eradication translates into decreased CRC incidence and mortality in large populations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/hel.70024 | DOI Listing |
J Biomater Appl
March 2025
Department of Chemistry, School of Pharmacy, North Sichuan Medical College, Nanchong, China.
Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide. Capecitabine is a chemotherapeutic agent commonly used for the treatment of colon cancer. To realize local sustained release, promote efficient local intracellular transport, and mitigate the systemic toxic effects of capecitabine, a capecitabine prodrug, capecitabine-poly (p-dioxanone) (Cap-PPDO), was successfully synthesized.
View Article and Find Full Text PDFGastroenterology
March 2025
Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Gastroenterology, Endocrinology, and Metabolism, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Int J Cancer
March 2025
Anal Neoplasia Clinic, Research, and Education Center, University of California, San Francisco, California, USA.
Cells
March 2025
Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México (UNAM), Tlalnepantla 54090, Mexico.
Metabolic reprogramming plays a crucial role in cancer biology and the mechanisms underlying its regulation represent a promising study area. In this regard, the discovery of non-coding RNAs opened a new regulatory landscape, which is in the early stages of investigation. Using a differential expression model of HOTAIR, we evaluated the expression level of metabolic enzymes, as well as the metabolites produced by glycolysis and glutaminolysis.
View Article and Find Full Text PDFCells
February 2025
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Although every cell biologist knows the importance of selecting the right growth conditions and it is well known that the composition of growth medium may vary depending on a product brand or lot affecting many cellular processes, still those effects are poorly systematized. We addressed this issue by comparing the effect of 12 fetal bovine sera (FBS) and eight growth media from different brands on the morphological and functional parameters of five cell types: lung adenocarcinoma, neuroblastoma, glioblastoma, embryonic kidney, and colorectal cancer cells. Using high-throughput imaging, we compared cell proliferation; performed morphological profiling based on the imaging of 561,519 cells; measured extracellular regulated kinases (ERK1/2) activity, mitochondria potential, and lysosome accumulation; and compared cell sensitivity to drugs, response to EGF stimulation, and ability to differentiate.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!